← SLU-PP-332 overview

SLU-PP-332 Dosage & Reconstitution Guide

⚠ No human data whatsoever; entirely experimental and not proven safe in people

Research and educational use only — not medical advice, and not for human consumption. The figures below are summarized from public sources, product labeling, and community reports, and are not a prescription or a substitute for a qualified clinician.

Typical dose
No established human dose; anecdotal SC protocols use roughly 250 mcg to 1 mg per day
Route
Subcutaneous injection
Frequency
once daily

Dosing schedule

The table below reports the doses used in the underlying research or by the community — it is documentation, not a recommendation to replicate at home.

Phase Dose Notes
Low 250 mcg Lower end of the anecdotal community range
Moderate 500 mcg Commonly cited midpoint; no human validation
High 1000 mcg Upper end reported anecdotally; safety unknown

Timing & cycling

Before exercise or in the morning

Cycle length. No established cycle; community use is short and experimental

Storage & handling

Keep the lyophilized (unmixed) vial refrigerated at 2–8 °C (36–46 °F) in a dry, dark place — it tolerates short periods at room temperature during shipping. Once reconstituted, store it at 2–8 °C, never frozen, and use it within about 2–4 weeks (sooner if the solution turns cloudy or discolored). Swab the stopper before every draw and use a fresh needle each time.

Key points

  • Entirely preclinical: all published data come from mice, not humans.
  • Branded an exercise mimetic because it activates ERR pathways that overlap with exercise.
  • No human pharmacokinetics, so dosing and frequency are pure extrapolation.
  • ERRs are active in heart tissue, making off-target cardiac effects a real unknown.
  • Sold for research use only and not evaluated by the FDA.

What to monitor

No validated markers; users informally track endurance, body composition, and heart rate

Legal & prescription status

Not FDA approved and not a prescription drug; preclinical research compound sold for research use only

References

  1. Billon et al., ACS Chem Biol (2023) - synthetic ERR agonist enhances exercise capacity
  2. Billon et al., J Pharmacol Exp Ther (2023) - ERR agonist alleviates metabolic syndrome
  3. SLU-PP-332 overview and cited references (Wikipedia)

This guide is for research and educational purposes only. It is not medical advice and does not describe a product approved for human use. Always consult a qualified healthcare professional before considering any peptide protocol.